Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Sees Large Decrease in Short Interest

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a significant drop in short interest in the month of October. As of October 30th, there was short interest totaling 4,226 shares, a drop of 92.6% from the October 15th total of 57,367 shares. Based on an average daily volume of 50,823 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Otsuka Stock Up 1.2%

OTCMKTS OTSKY traded up $0.46 on Thursday, hitting $38.36. 8,486 shares of the company were exchanged, compared to its average volume of 41,144. The company has a current ratio of 2.21, a quick ratio of 1.65 and a debt-to-equity ratio of 0.05. The company has a market cap of $41.21 billion, a PE ratio of 16.46, a PEG ratio of 2.72 and a beta of 0.08. The stock has a fifty day moving average of $37.28 and a 200-day moving average of $35.19. Otsuka has a 12 month low of $26.11 and a 12 month high of $40.92.

Otsuka (OTCMKTS:OTSKY) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. The firm had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.42 billion. Otsuka had a net margin of 14.36% and a return on equity of 11.90%. As a group, analysts forecast that Otsuka will post 2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered Otsuka from a “strong-buy” rating to a “hold” rating in a research note on Monday. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Otsuka presently has a consensus rating of “Hold”.

About Otsuka

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.